Myeloma | Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Darzalex Combination Granted Priority Review for Myeloma Treatment

January 22nd 2018

The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).

Kyprolis Label Update Approved for Myeloma Treatment

January 18th 2018

The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.

Despite Clinical Efficacy, Only Certain Myeloma Treatments Are Cost-Effective

January 17th 2018

Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.

Ancient History: Two Mummies Discovered With Cancer

January 17th 2018

The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.

Xgeva Approved to Prevent Skeletal-Related Events in Patients With Myeloma

January 5th 2018

Xgeva (denosumab) was granted approval by the Food and Drug Administration (FDA) to prevent skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the drug.

Popular Myeloma Drug Associated With Higher Rates of Heart Toxicity

January 5th 2018

A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.

Timely Hospice Use Increases Among Patients with Myeloma

January 1st 2018

Researchers found a significant trend toward increased hospice use by people who have multiple myeloma between 2010 and 2013, which indicates that they are receiving more effective pain management toward the end of their lives.

Star-Studded Event Raises Funds for the Prevention and Cure of Multiple Myeloma

December 29th 2017

Hosted by comedian, actor and star of “Everybody Loves Raymond” Ray Romano, the 11th Annual Comedy Celebration raised $600,000 to support the work of the International Myeloma Foundation (IMF).

Predictors Can Help Doctors Ensure Patients Have More Time Spent at Home

December 16th 2017

Patients with blood cancers typically value time spent at home in their end-of-life care, however, health care systemts do not always prioritize this in their own quality measures.

Cross-Country Biking for a Cure Turns Out to Be So Much More

December 15th 2017

A team of six bicyclists trekked across country, from California to Connecticut, to fundraise for the Multiple Myeloma Research Foundation.

What Comes Next for Cancer Survivors?

December 4th 2017

At the National Comprehensive Cancer Network® (NCCN)’s Patient Advocacy Summit – a meeting designed to share best practices for survivorship planning care among advocacy organizations – Yelak Biru shared his story of survivorship, and how he has been able to integrate multiple myeloma into his life for more than two decades.

Exciting Developments in the Treatment of Multiple Myeloma

December 1st 2017

A researcher discusses the exciting times surrounding the development of novel agents designed to treat multiple myeloma.

What Patients With Cancer Can Learn from Savvy Shoppers

November 9th 2017

Don’t people with cancer, as consumers of health care, deserve an equally personalized approach to cancer treatment as we have come to expect in other areas of our daily life?

Combinations, Sequencing Being Explored in Myeloma

November 8th 2017

New treatment regimens may be hitting the scene of myeloma treatment.

Myeloma Treatment Standards Continue to Evolve

November 6th 2017

Alfred L. Garfall lends insight as to what is new for myeloma treatment.

Drug Granted Breakthrough Status to Treat Relapsed or Refractory Myeloma

November 3rd 2017

A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.

Higher-Dose, Less Frequent Kyprolis Benefits Patients With Myeloma

October 25th 2017

Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.

Expert Talks Treating Newly Diagnosed Patients With Myeloma

October 15th 2017

The way that newly diagnosed patients with multiple myeloma is treated has changed significantly over recent years, especially as new drugs moved into the treatment realm for the disease, says Shaji K. Kumar, M.D.

Improving Treatment for Elderly Patients With Myeloma

October 13th 2017

Several questions still remain regarding the treatment strategies for elderly patients with multiple myeloma, many of whom may have other comorbidities or trouble tolerating therapies.

Individualized Treatment Needed for Relapsed, Refractory Multiple Myeloma

October 10th 2017

Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.

Myeloma Specialists Share Their Treatment Strategies

September 27th 2017

Experts in multiple myeloma share the newest information on the goals of therapy in symptomatic disease, testing for minimal residual disease, the role of transplantation, and the use of maintenance therapy.

Acupuncture Reduces Symptom Burden in Patients With Multiple Myeloma

September 27th 2017

Acupuncture is a powerful resource that has been around for thousands of years. The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment.

Survival Rates Increase Faster Than Costs in Myeloma

September 27th 2017

For people with multiple myeloma, dollars spent on treatment are being stretched farther than they used to be, a recent study shows.

Patient Advocacy Contributes to Progress in Multiple Myeloma Treatment

September 14th 2017

David S. Siegel, M.D., Ph.D., chief of the division of Multiple Myeloma at the John Theurer Cancer Center, attributes some of the progress in myeloma treatment to patients and how they advocate for themselves.

FDA Provides an Update on Halted Myeloma Trials

September 7th 2017

The Food and Drug Administration (FDA) recently released a statement providing data from the two phase 3 trials testing Keytruda (pembrolizumab) in patients with multiple myeloma. The trials were placed on clinical holds by the FDA in July, after concerns arose regarding the drug’s safety in this group of patients.

XPO1 Inhibitor Offers Novel Mechanism for Treating Penta-Refractory Myeloma

August 23rd 2017

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Expert Talks Advancements in Multiple Myeloma Treatment

August 14th 2017

Peter Voorhees, M.D., discusses the advancements in multiple myeloma treatment, as well as where he hopes the field will go in coming years.

FDA Approves Darzalex Combination for Myeloma Treatment

June 16th 2017

The Food and Drug Administration (FDA) granted an approval to Darzalex (daratumumab) for use in combination with Pomalyst (pomalidomide) and dexamethasone for patients who have multiple myeloma who have two or more prior therapies, including a proteasome inhibitor and Revlimid (lenalidomide).

Myeloma Immunotherapy Trials Paused

June 13th 2017

Merck will be pausing two trials testing Keytruda in patients with multiple myeloma.

Therapy Shows High Remission Rates in Multiple Myeloma

June 6th 2017

Many patients with relapsed or refractory multiple myeloma saw clinical remission with CAR T-cell therapy.

NEXT PAGE
PREVIOUS PAGE